MiniMed 780G Advanced Hybrid Closed-Loop System Outcomes According to Pubertal Status: Awesome Study Group Real-Life Experience

Achieving good glycemic control is a major challenge for adolescents with type 1 diabetes (TID). The introduction of the MiniMed 780G system, an advanced hybrid closed-loop (AHCL) that enables an automatic correction of insulin, gave hope for improved glycemic outcomes in adolescents. We assessed specific characteristics associated with glycemic measures in youth with T1D switching to Minimed 780G. This retrospective observational real-life multicenter study from the AWeSoMe Group assessed continuous glucose monitoring (CGM) metrics of 22 patients (59% females, median age 13.9 interquartile range [IQR 11,18] years), from a high socioeconomic background. CGM metrics were recorded for 2-week periods before AHCL, after 1, 3, 6 months, and at the end of follow-up (median 10.9 [IQR 5.4, 17.4] months). Delta-variables (Δ) were calculated as the difference between the end of follow-up and baseline. Time in range (TIR) increased from 65% [52, 72] to 75% [63, 80], = 0.008, from baseline to end of follow-up. Time above range decreased from 28% [20, 46] to 22% [14, 35], = 0.047. Advanced pubertal stage was correlated with less improvement in ΔTAR , = 0.47, = 0.05, and less CGM usage = -0.57, = 0.05. A longer disease duration was associated with less improvement in ΔTAR , = 0.48, = 0.05. Lower pump site change frequency was associated with higher glucose management indicator, = 0.5, = 0.03, and lower TIR = -0.52, = 0.08. The use of AHCL enabled improvements in TIR in youth with T1D. More advanced pubertal stages, longer disease duration, and less compliance were associated with less improvement, stressing the need for continuous support, and re-education in this age group.